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Abstract
Background
There is variability in clinical outcome for patients with apparently the same stage colorectal
cancer (CRC). Single nucleotide polymorphisms (SNPs) mapping to chromosomes 1q41,
3q26.2, 6p21, 8q23.3, 8q24.21, 10p14, 11q13, 11q23.1, 12q13.13, 14q22, 14q22.2,
15q13.3, 16q22.1, 18q21.1, 19q13.11, 20p12, 20p12.3, 20q13.33 and Xp22 have robustly
been shown to be associated with the risk of developing CRC. Since germline variation can
also influence patient outcome the relationship between these SNPs and patient survivor-
ship from CRC was examined.
Methods
All enrolled into the National Study of Colorectal Cancer Genetics (NSCCG) were geno-
typed for 1q41, 3q26.2, 6p21, 8q23.3, 8q24.21, 10p14, 11q13, 11q23.1, 12q13.13, 14q22,
14q22.2, 15q13.3, 16q22.1, 18q21.1, 19q13.11, 20p12, 20p12.3, 20q13.33 and xp22
SNPs. Linking this information to the National Cancer Data Repository allowed patient ge-
notype to be related to survival.
Results
The linked dataset consisted of 4,327 individuals. 14q22.22 genotype defined by the SNP
rs4444235 showed a significant association with overall survival. Specifically, the C allele
was associated with poorer observed survival (per allele hazard ratio 1.13, 95% confidence
interval 1.05–1.22, P = 0.0015).
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Conclusion
The CRC susceptibility SNP rs4444235 also appears to exert an influence in modulating pa-
tient survival and warrants further evaluation as a potential prognostic marker.
INTRODUCTION
Colorectal cancer (CRC) is a common disease in the UK affecting around 40,000 individuals
annually and accounting for 16,000 cancer related deaths each year [1]. Despite major advances
in the medical management of CRC over the last 25 years, five-year survival remains at only
around 55% [1].
A principle metric of patient prognosis of CRC is stage at presentation [2] however there is
significant variability in overall survival (OS) of patients with apparently same stage disease
and understanding these differences is clinically important.
There is evidence of familial concordance for survival in a number of cancers, including
CRC [3], which suggests that inherited genetic variation can contribute to CRC prognosis. Ad-
ditionally, studies have reported associations with survival from CRC with genetic variants
alone or in combination with specific types of chemotherapy [4–6]. Hence, as a potential prog-
nostic factor the concept of germline variation imparting inter-individual variability in tumour
development, progression and metastasis is receiving increased attention [7–11].
Genome-wide association studies (GWAS) have been successful in identifying single nucle-
otide polymorphisms (SNPs) that are significantly associated with an individual’s risk of devel-
oping a CRC [12,13]. In European populations GWAS located CRC susceptibility SNPs have
been identified at 1q41, 3q26.2, 5p15.33, 6p21, 8q23.3, 8q24.21, 10p14, 11q13.4, 11q23.11,
12q13.3, 14q22.2, 15q13.3, 16q22.1, 18q21.1, 19q13, 20p12.3, 20q13.33, and Xp22.2 [12–16].
As well as influencing CRC risk, it is entirely plausible these variants may also impact on pa-
tient outcome following the diagnosis of CRC.
This hypothesis has been variously examined by a number of researchers but with contra-
dictory results [17–24]. Disparity may be due to the relatively small and heterogeneous cohorts
of individuals analysed which had limited power to detect clinically important relationships be-
tween SNP genotype and outcome and, hence, the prognostic significance of these CRC suscep-
tibility variants remains controversial. To address shortcomings in previous studies we have
made use of the recent linkage [10] of the large National Study of Colorectal Cancer Genetics
(NSCCG) [25] with the data in the National Cancer Data Repository (NCDR) [26]. This link-
age has offered an opportunity to relate genotype and outcome across a larger population than
has previously been possible. Using these data, this study aimed to investigate whether 19 CRC
susceptibility SNPs also exerted an influence of survival from the disease.
MATERIALS ANDMETHODS
Patients and record linkage
Full details of the NSCCG have been published elsewhere [25] but, in brief, the study collected
DNA and clinicopathological data from over 20,000 individuals with colorectal cancer and a
series of spouse/partner controls with the aim of creating a unique resource for the identifying
low-penetrance CRC susceptibility genes. All individuals within this study for whom SNP in-
formation were available and who could be linked to the NCDR were, therefore, identified and
matched using the method described previously [10]. To minimise bias, cases were excluded
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from the analysis if there was more than a year between the diagnosis of CRC in an individual
recorded in the NCDR and their recruitment to the NSCCG (Fig. 1).
All clinical information and biological samples were obtained after fully informed consent
was obtained from participating individuals, and in accordance with the tenets of the Declara-
tion of Helsinki. Ethical approval for the both the NSCCG and its linkage to the NCDR were
obtained fromMulti-Centre Research Ethics Committees (MREC/98/2/67; MREC02/0/97;
REC08/S0501/66)
Genotyping
DNA was extracted from EDTA acid-venous blood samples by conventional methodologies
and PicoGreen quantified (Invitrogen Corporation, Carlsbad, California; now Life Technolo-
gies). Nineteen SNPs were selected that had been reported to be associated with CRC from 14
chromosomal regions—rs6691170 (1q41), rs10936599 (3q26.2), rs1321311 (6p21), rs16892766
(8q23.3), rs6983267 (8q24.21) rs10795668 (10p14), rs3824999 (11q13), rs3802842 (11q23.1),
rs11169552 (12q13.13), rs1957637 (14q22), rs4444235 (14q22.2), rs4779584, (15q13.3),
rs9929218 (16q22.1), rs4939827 (18q21.1), rs10411210 (19q13.11), rs4813802 (20p12),
rs961253 (20p12.3) rs4925386 (20q13.33) and rs5934682 (xp22). SNP genotyping was per-
formed by allele-specific polymerase chain reaction (LGC Genomics; http://www.kbioscience.
co.uk) with primer sequences and conditions available on request. To monitor quality control,
we included a set of 136 duplicate samples in assays; genotype concordance was>99.9%. To
confirm genotypes, we sequenced 192 samples chosen randomly from cases and controls; con-
cordance between genotypes was 100%.
Statistical analysis
Statistical analyses were conducted using Stata version 13 (State College, Tx, USA). A P-value
of 0.05 (two sided) was considered to be significant. When commented, a Bonferroni correc-
tion for multiple comparisons corresponded to a value of 0.0026 (0.05/19 SNPs). Results are
presented without correction for multiple testing to mitigate against type II error. Differences
Fig 1. Matching of the NSSCG study cohort and the NCDR.
doi:10.1371/journal.pone.0117816.g001
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in patient characteristics between groups were assessed using χ2 and Kruskal-Wallis tests. The
study end-point was five-year overall survival calculated from date of recruitment to the
NSCCG to date of death or when censored (30th June 2011). Kaplan-Meier graphs according to
genotype were generated and their homogeneity evaluated using log-rank tests. Cox propor-
tional hazards regression analysis was used to estimate hazard ratios (HR) and their 95% confi-
dence intervals (CI) whilst adjusting for age, sex, Dukes’ stage of disease at diagnosis,
deprivation score, tumour site (colon, rectosigmoid junction or rectum), and year of diagnosis.
The P-values presented correspond to the significance of a test difference among all three of
the genotype groups (common allele homozygote, heterozygote and rare allele homozygote).
The power to demonstrate a relationship between SNP genotype and OS was estimated
using sample size formulae for comparative binomial trials. To evaluate the chance of obtaining
a false-positive association in our data set and to assess the robustness of previously reported
associations between SNP genotype and patient outcome, we made use of the false-positive
report probability (FPRP) test [27]. The FPRP value is determined by the P value, the prior
probability for the association, and statistical power. For our analyses, we assumed prior proba-
bilities of 0.05, 0.01 and 0.001; imposing an FPRP cut-off value of 0.5 as advocated [27], values
less than 0.5 were considered to be noteworthy, being indicative of a robust association.
Meta-analysis of study findings with previously published data was performed using a
fixed-effects model, estimating Cochran’s Q statistic to test for heterogeneity and the I2 statistic
to quantify the proportion of the total variation between studies.
Ethical approval was obtained for both the NSCCG study (MREC/98/2/67; MREC02/0/97)
and the linkage and exploitation of the NSCCG and NCDR data (LR/08/S0501/66).
RESULTS
Linkage
Information on 9,229 individuals recruited to the NSCCG and with SNP information was sup-
plied for linkage to the NCDR. The study population consisted of 4,327 (46.9%) of these indi-
viduals who both matched into the NCDR and who were recruited to the NSCCG within a year
of the diagnosis of their disease (Fig. 1).
Descriptive statistics
Complete clinical and demographic characteristics of the subjects studied are provided in
Table 1. The median age at diagnosis of CRC was 60 years (mean, 58.6 years; standard devia-
tion, 8.0). A total of 2,626 cases (60.7%) had colonic, 416 (9.6%) rectosigmoid and 1,285
(29.7%) rectal tumours; the majority of patients presented with Dukes’ stage B and C tumours
(3,055, 70.6%).
Overall, the 5-year survival rate was 64.3% (95%CI 62.9–65.8%). There were 1,658
(38.3%) deaths across the entire cohort. Survival was strongly associated with tumour stage
(P<0.0001); 5-year survival ranged from 54.9% (95%CI 0.50–0.60) for patients diagnosed with
stage D CRC to 88.4% (95%CI 83.6–91.2%) for those with the stage A CRC. Since these survival
rates are not significantly different to those documented in previously published studies inves-
tigating the prognosis of actively managed CRC patients [28], it was concluded that there is no
evidence that ‘healthy study participant’ selection would bias analyses.
Relationship between SNP genotype and OS
There was no statistically significant correlation between SNP genotype and the pathological
parameters, site and stage. Only one SNP showed evidence of a correlation with OS (Table 2).
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A significant association were identified between rs4444235 genotype and prognosis, where the
hazards ratio for increasing number of variant alleles was 1.13 (95% CI: 1.05–1.22). Hazard ra-
tios for heterozygosity, homozygosity and carrier status were: 1.18 (95% CI: 1.04–1.34) and
1.28 (95% CI: 1.11–1.48), respectively. It should be noted that the association (Ptrend = 0.0015)
remained significant if Bonferroni correction for multiple testing was applied (Padj = 0.032)
and remained noteworthy (i.e. FPRP0.5) provided the prior was>0.001. Kaplan–Meier esti-
mates (Fig. 2) demonstrated that carriers had lower five-year survival than those with the wild-
type genotype (P<0.01).
Table 1. The characteristics of the study population.
Characteristic n %
Median age at diagnosis (range) 60 (54–65)
Age at diagnosis 50 631 14.6
51–60 1,648 38.1
>60 2,048 2,048
Sex Male 2,570 59.4
Female 1,757 40.6
Self-reported family history of colorectal cancer No 3,500 80.9
Yes 827 19.1
Dukes' stage of disease at diagnosis A 252 5.8
B 1,171 27.1
C 1,884 43.5
D 596 13.8
Unknown 424 9.8
Tumour site Colon 2,626 60.7
Rectosigmoid 416 9.6
Rectum 1,285 29.7
IMD income category Most afﬂuent 1,066 24.6
2 1,016 23.5
3 979 22.6
4 739 17.1
Most deprived 527 12.2
Year of recruitment into NSCCG 2004 789 18.2
2005 1,489 34.4
2006 1,073 24.8
2007 813 18.8
2008 67 1.6
2009 50 1.2
2010 46 1.1
Year of diagnosis of CRC 2003 190 4.4
2004 1,277 29.5
2005 1,292 29.9
2006 1,074 24.8
2007 366 8.5
2008 58 1.3
2009 61 1.4
2010 9 0.2
doi:10.1371/journal.pone.0117816.t001
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Commentary on previously published studies
A number of previous studies have evaluated the relationship of rs4444235 and other risk
SNPs with patient prognosis (Table 3). Tenesa et a l [21] analysed 10 CRC susceptibility vari-
ants but found no association with OS or CRC-specific survival (CSS). Xing et al [22] analysed
six SNPs in a small cohort of patients in relation to recurrence and death and generated evi-
dence suggesting that rs10795668 (10p14) might influence recurrence (P = 0.007, Padj = 0.042).
The effect observed was strongest in those receiving chemotherapy. Phipps et al [20] studied 16
CRC SNPs (including some also analysed by Tenesa et al [21] and survival in 2,611 CRC pa-
tients ascertained from five cohort studies. They reported the 18q21 variant rs4939827 affected
OS (P = 0.002; Padj = 0.03). Most recently Abuli and co-workers [17] reported on the relation-
ship between 16 CRC risk SNPs CRC patients requited to the Spanish EPICOLON consortium.
Genetic variants rs9929218 at 16q22.1 and rs10795668 at 10p14 were reported to have an effect
on OS (P = 0.0179 and 0.057, respectively) albeit neither robust after adjustment for multiple
testing (Padj = 0.28 and 0.91, respectively). Most recently, Hoskins et al [19] have reported on
the relationship between 11 SNPs and survival. The only associations reported to be significant
was for homozgosity for 8q24 SNPs rs7013278, rs7014346 (P = 0.01 and 0.03 respectively, Padj
for number of risk loci = 0.06 and 0.18 respectively). Contemporaneously Dai and co-workers
[18] reported on the relationship between 26 SNPs in 10 of the GWAS risk loci in a cohort re-
stricted to individuals with Dukes’ stage B and C cancers. rs961253 (20p12.3), rs355527
(20p12.3), rs4464148 (18q21.1), rs6983267 (8q24.21) and rs10505477 (8q24.21) were signifi-
cantly associated with survival. The effects were no longer statistically significant, however,
after adjustment for multiple testing. Irrespective of correction for multiple testing assuming a
prior of 0.001 none of these associations are inherently robust.
Table 2. Unadjusted and risk-adjusted hazard ratios showing the risk of death within ﬁve years of diagnosis in relation to SNP status.
SNP Position
(nearest gene)
Risk allele Number of individuals Number of deaths Unadjusted Adjusted
HR 95% CI P value HR 95% CI P value
rs10411210 19q13 C 4,275 1,632 1.02 0.90–1.16 0.76 1.07 0.94–1.22 0.30
rs10795668 10p14 G 4,171 1,600 1.06 0.98–1.15 0.16 1.04 0.96–1.13 0.34
rs10936599 3q26 C 4,285 1,640 1.05 0.96–1.14 0.26 1.07 0.99–1.17 0.10
rs11169552 12q13 C 4,257 1,632 1.01 0.93–1.10 0.75 1.04 0.96–1.14 0.33
rs1321311 6p21 C 4,254 1,626 1.00 0.92–1.08 0.94 0.98 0.90–1.07 0.62
rs16892766 8q23 C 4,270 1,633 0.93 0.82–1.05 0.23 0.94 0.83–1.06 0.32
rs1957637 14q22 A 4,303 1,647 1.00 0.93–1.07 0.98 0.97 0.90–1.04 0.34
rs3802842 11q23 C 4,244 1,625 0.97 0.90–1.05 0.48 0.97 0.90–1.05 0.50
rs3824999 11q13 A 4,263 1,634 0.99 0.92–1.06 0.77 1.02 0.95–1.10 0.58
rs4444235 14q22 C 4,278 1,638 1.12 1.04–1.50 0.001 1.13 1.05–1.22 0.001
rs4779584 15q13 T 4,251 1,624 1.02 0.94–1.11 0.69 1.01 0.93–1.10 0.85
rs4813802 20p12 G 4,223 1,615 0.98 0.91–1.06 0.59 0.98 0.91–1.06 0.64
rs4925386 20q13 C 4,263 1,630 1.06 0.97–1. 14 0.19 1.09 1.01–1.18 0.03
rs4939827 18q21 T 4,268 1,630 0.97 0.91–1.05 0.47 0.94 0.87–1.01 0.08
rs5934683 Xp22 C 4,225 1,608 0.98 0.92–1.04 0.51 0.96 0.90–1.02 0.14
rs6691170 1q41 T 4,266 1,632 1.01 0.94–1.09 0.75 1.05 0.97–1.13 0.22
rs6983267 8q24 G 4,246 1,623 1.07 0.99–1.12 0.08 1.05 0.98–1.13 0.16
rs961253 20p12 A 4,249 1,624 0.92 0.86–1.00 0.05 0.97 0.90–1.04 0.40
rs9929218 16q22 G 4,271 1,634 1.01 0.94–1.10 0.73 1.01 0.93–1.10 0.76
doi:10.1371/journal.pone.0117816.t002
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Only two of the previously reported studies have investigated the influence of rs4444235 on
prognosis and they found no significant association with survival [20,21]. To further examine
the association between rs4444235 genotype and OS a meta-analysis pooling our study with
these studies was undertaken (Fig. 3). Collectively, the three studies provided rs4444235 geno-
types on a total of 9,686 CRC patients. Using these data, the summary OR was 1.08 (95%CI
1.02–1.14) with the potential of heterogeneity between studies (Phet = 0.34; I
2 = 8%).
DISCUSSION
Here we have provided evidence that variation at 14q22.2 defined by rs4444235 influences
CRC outcome independent of established metrics. Although our study did not provide evi-
dence for a relationship between other SNPs our analysis only had 50–70% power to demon-
strate a relationship between carrier status for a 10% difference in prognosis, at the 5%
threshold. Hence it is not possible to conclusively exclude the possibility that variation at the
other CRC risk loci may also be linked to outcome.
Major strengths of our study are its size, the fact that it is drawn from a representative sam-
ple of the population, and involved the systematic follow-up of patients. Overall survivorship is
unlikely to have influenced study findings, even though case selection in NSCCG is biased to
Dukes’ stages A and B disease. It therefore seems unlikely that any spurious influences as a
Fig 2. Kaplan Meier survival curves for SNP rs4444235.
doi:10.1371/journal.pone.0117816.g002
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consequence of study design will have impacted significantly on our findings. Furthermore, as
our analysis was restricted to UK patients with self-reported European ethnicity our study find-
ings are also unlikely to be confounded by population stratification.
We do however acknowledge that a limitation of our study is that we have not addressed po-
tential bias arising from non-uniform treatment. While this is a potential serious confounder
in studies of some tumours the management of CRC is relatively uniform within the UK. Sup-
port for this assertion is provided by the fact that survival rates observed in our study popula-
tion were not different to those expected of other unselected patients of a similar stage profile
treated in the UK [2]. It is likely that the impact of risk variants will be contingent upon inter-
action with non-genetic risk factors. Unfortunately, such data were not available within the
current study to allow such an analysis.
Mechanistically a functional basis for only the 14q22.2 association has yet to be fully eluci-
dated. It is also noteworthy that the risk allele of rs4444235 appears to be preferentially associ-
ated with the development of microsatellite stable CRC[29,30]. This is consistent with the
observation that germline mutation in the TGF-β superfamily-signalling pathway genes is asso-
ciated with microsatellite stable CRC, and hence may impact indirectly on patient outcome.
Furthermore, reporter gene studies have demonstrated that the element to which rs4444235
maps acts as an allele-specific transcriptional enhancer. Allele-specific expression studies in
CRC cell lines heterozygous for rs4444235 have shown significantly increased expression of
bone morphogenetic protein-4 (BMP4) associated with the risk allele providing evidence for a
functional basis for the non-coding risk variant [31].
This analysis has provided evidence that variation in 14q22.2 plays a role in defining indi-
vidual patient prognosis. However compelling this association between 14q22.2 and OS is on
Fig 3. Forest plot showing the results of a meta-analysis combining HR for the SNP rs4444235. Horizontal lines represent 95% confidence intervals.
Each box represents the OR point estimate and its area is proportional to the weight of the study. The diamond (and unbroken line) denotes the overall
summary estimate, with CIs given by its width. The unbroken vertical line is at the null value (OR = 1.0).
doi:10.1371/journal.pone.0117816.g003
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the basis of biological plausibility as with all association studies independent validation of
study findings is required. While previously published studies have not provided support for
the 14q22.2 association such studies are small and hence have had limited power to demon-
strate a relationship[17–24,32]. Hence our analysis serves to highlight the statistical problem of
searching for genetic associations when the impact of any variant is likely to be at best modest.
Even stipulating significance level of 0.05 for an analysis of clinical trial data is unrealistic, be-
cause to have 80% power to demonstrate a 5% difference in survival, which is clinically rele-
vant, requires at least 4,800 patient samples to be analysed, even if the frequency of the at risk
genotype is 50%. Hence it is therefore not perhaps surprising that previously purported associ-
ations cannot be considered robust if FPRP type criteria are imposed.
While germline variants are unlikely to replace staging schemes and conventional markers,
they have potential to assist in distinguishing different outcome patterns among patients with
the same stage disease where 10% differences are clinically relevant thereby opening up the
possibility of a rational, targeted approach to treatment based on a combination of genotype
and tumour characteristics of a patient.
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